Neoadjuvant immune checkpoint inhibitors in cancer, current state of the art - Centre de recherche en cancérologie de Lyon (UMR INSERM 1052 ; CNRS 5286 ; Centre Léon Bérard) Accéder directement au contenu
Article Dans Une Revue Critical Reviews in Oncology/Hematology Année : 2021

Neoadjuvant immune checkpoint inhibitors in cancer, current state of the art

Résumé

Immunotherapy has been a revolution in cancer management in the metastatic setting. This has led to a prompt evaluation of such therapies in earlier stages. This article discusses the still limited amount of data finding the rationale to assess such therapy in this setting and reviews preclinical and clinical data available. Overall, neoadjuvant immunotherapy is a promising approach for the treatment of cancers and the rationale supporting its use is strong. Neoadjuvant immunotherapy resulted, in the majority of clinical trials, in improved pathologic complete response rates with a favorable toxicity profile and no delay in surgery. Various regimens were effective: inhibitory immune check-point blockers (IICPB) alone, combination of PD-1 and CTLA-4 inhibitors, combination of chemotherapy (CT) and IICPB, phased CT and IICPB (either IICPB before CT or IICPB after CT). Yet the question whether neoadjuvant immunotherapy will benefit to patients in terms of disease-free and, ultimately, overall survival remains unknown.
Fichier principal
Vignette du fichier
S1040842820303085.pdf (755.98 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03492630 , version 1 (15-12-2022)

Licence

Paternité - Pas d'utilisation commerciale

Identifiants

Citer

Olivia Le Saux, Yasmine Lounici, Pauline Wajda, Sarah Barrin, Christophe Caux, et al.. Neoadjuvant immune checkpoint inhibitors in cancer, current state of the art. Critical Reviews in Oncology/Hematology, 2021, 157, pp.103172 -. ⟨10.1016/j.critrevonc.2020.103172⟩. ⟨hal-03492630⟩
23 Consultations
38 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More